Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | CA7 | P43166 | 2/20 | 0.56 |
| ▸ | CA9 | Q16790 | 2/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | TSHR | P16473 | 6/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | PRKCG | P05129 | 1/20 | 0.50 |
| ▸ | PRKCB | P05771 | 1/20 | 0.50 |
| ▸ | PRKCA | P17252 | 1/20 | 0.50 |
| ▸ | PRKACA | P17612 | 1/20 | 0.50 |
| ▸ | PRKACG | P22612 | 1/20 | 0.50 |
| ▸ | PRKACB | P22694 | 1/20 | 0.50 |
| ▸ | PRKCH | P24723 | 1/20 | 0.50 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.50 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10880068 | 0.92 | ALDH1A1 (0.66) | CA12CA1CA2CA7CA9 | |
| Methyl Salicylate SCHEMBL9229811 | 0.84 | TSHR (0.71) | ALDH1A1TSHRLMNATDP1L3MBTL1 | |
| SCHEMBL29453452 | 0.84 | CA1 (0.80) | CA12CA1CA2CA7CA9 | |
| SCHEMBL157121 | 0.84 | CA1 (0.80) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28264615 | 0.83 | TSHR (0.68) | CA12CA1CA2CA7CA9 | |
| SCHEMBL22289781 | 0.82 | ALDH1A1 (0.75) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5164954 | 0.80 | ALDH1A1 (0.85) | ALDH1A1TSHRLMNATDP1L3MBTL1 | |
| SCHEMBL10882650 | 0.79 | CA12 (0.82) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5788119 | 0.78 | ALDH1A1 (0.68) | CA12CA1CA2CA7CA9 | |
| Methyl Salicylate SCHEMBL28108938 | 0.77 | TSHR (0.59) | CA1CA2CA9ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12023365-B2 | Sustained release formulations of Crocus sativus | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2024-07-02 | — | — | US | disclosed |
| WO-2024073056-A1 | CUCURBITURIL COMPOSITIONS, PRODUCTS, AND METHODS OF USE | Kureha America, Inc. (US) | 2024-04-04 | — | — | WO | disclosed |
| US-20200390843-A1 | SUSTAINED RELEASE FORMULATIONS OF CROCUS SATIVUS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2020-12-17 | — | — | US | disclosed |
| EP-3697389-A1 | SUSTAINED RELEASE FORMULATIONS OFCROCUS SATIVUS | Council of Scientific and Industrial Research (IN) | 2020-08-26 | — | — | EP | disclosed |
| WO-2019077621-A1 | SUSTAINED RELEASE FORMULATIONS OF CROCUS SATIVUS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2019-04-25 | — | — | WO | disclosed |
| EP-1257269-B1 | ORALLY ADMINISTRABLE ACID STABLE ANTI-ULCER BENZIMIDAZOLE DERIVATIVES | KOPRAN RES LAB LTD (IN) | 2004-11-03 | — | — | EP | disclosed |
| US-6617338-B2 | Orally administrable acid stable antiulcer benzimidazole derivatives | KOPRAN RESEARCH LABORATORIES LIMITED (IN) | 2003-09-09 | — | — | US | disclosed |
| US-20030023091-A9 | Orally administrable acid stable antiulcer benzimidazole derivatives | KOPRAN RESEARCH LABORATORIES LIMITED (IN) | 2003-01-30 | — | — | US | disclosed |
| EP-1257269-A1 | ORALLY ADMINISTRABLE ACID STABLE ANTI-ULCER BENZIMIDAZOLE DERIVATIVES | Kopran Research Laboratories Limited (IN) | 2002-11-20 | — | — | EP | disclosed |
| US-20020038032-A1 | Orally administrable acid stable antiulcer benzimidazole derivatives | KOPRAN RESEARCH LABORATORIES LIMITED (IN) | 2002-03-28 | — | — | US | disclosed |
| WO-2001062248-A1 | ORALLY ADMINISTRABLE ACID STABLE ANTI-ULCER BENZIMIDAZOLE DERIVATIVES | KOPRAN RESEARCH LABORATORIES LIMITED (IN) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030023091-A9 | Orally administrable acid stable antiulcer benzimidazole derivatives | SI, PGA5, PAICS | CA12 1535/4885CA1 1573/4885CA2 430/4885 |
| US-20020038032-A1 | Orally administrable acid stable antiulcer benzimidazole derivatives | SI, PGA5, PAICS | CA12 1535/4885CA1 1573/4885CA2 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.